INTERLEUKIN 36 MEDIATES INTESTINAL INFLAMMATION AND FIBROSIS VIA MATRIX METALLOPROTEINASE 13

Background: Mesenteric fat wrapping around the intestinal wall, so called ‘creeping fat’ (CF), is spatially linked with stricture formation in Crohn’s disease (CD). Intestinal muscularis propria (MP) smooth muscle cell (HIMC) hyperplasia is a major contributor to luminal narrowing in stricturing CD. We investigated CF derived factors and their effect on HIMC hyperplasia in vitro and in vivo.

Methods: Secretion of free fatty acids (FFA) by mesenteric fat (MF) or CF organ cultures was determined via lipidomic mass spectrometry. Effects of different length and types of FFA as well as CF and MF conditioned medium on proliferation of primary HIMF was assessed. Next generation sequencing (NGS) and lipidomics was performed on HIMF and relevant pathways were inhibited with small molecules or siRNA knockdown. In the dextran sodium sulfate (DSS) induced colitis model fat deletion was accomplished using the transgenic FAT-ATTAC mouse and CPT-1 blockade was achieved via the small molecule etomoxir.

Results: Histopathology of intestinal resection tissues revealed CD CF being located in the subserosa and its presence was linked with dramatic thickening of the MP. MP thickening was also observed in the acute DSS colitis model compared to controls and the thickening was reduced by fat deletion in the FAT-ATTAC mouse. CF conditioned medium markedly upregulated HIMC proliferation compared to mesenteric fat from CD, UC and normal controls. CF released higher amounts of total, saturated and poly-unsaturated FFA with elevated levels of five long-chain (LC-)FFA, including palmitate. LC, but not medium or short chain FFA selectively increased proliferation in HIMC and fibroblasts, but not other intestinal cell types. NGS revealed gene regulation suggesting LC-FFA transport as a putative mechanism. Lipidomic analysis indicated the majority of palmitate being converted into phospholipids, predominantly phosphatidylcholine. Inhibition of LC-FFA uptake into cells via CD36, metabolism through inhibition of acyl-CoA synthetase, choline-phosphate cytidylyltransferase & choline kinase or blockade of LC-FFA uptake into mitochondria through CPT-1A reduced palmitate and CF conditioned medium induced HIMC proliferation. Prophylactic inhibition of CPT-1 with etomoxir in acute DSS colitis did not reduce histopathologic inflammation or inflammatory cytokines gene expression, but reduced MP thickness and gene expression of the smooth muscle cell genes Desmin and Sm22.

Conclusion: Subserosal CF releases LC-FFA inducing a selective proliferative response by HIMC. This effect was dependent on CD36, acyl-CoA synthetase and CPT-1. LC-FFA taken up by HIMC are converted into phospholipids. Deletion of fat or inhibition of CPT-1 in acute DSS colitis reduced the increased MP thickness in proximity to mesenteric fat. These results point to CF as a novel contributor to stricture formation in CD.

Intestinal fibrosis is a common complication in patients suffering from Crohn’s disease (CD). Dysbalanced extracellular matrix deposition leads to thickening of the intestinal wall resulting in stenotic strictures that require surgical interventions, whereas medical therapy of stricturing CD represents a high unmet need. Previous work provided evidence that Interleukin 36 receptor (IL36R) activation is connected with intestinal inflammation and fibrosis. Correspondingly, the targeting of IL36R signaling as therapy option in IBD including CD patients with stenosis is currently investigated. However, the mechanisms mediated by IL36R signaling in the context of intestinal fibrosis are only partly understood. Here, we studied the contribution of the IL36-inducible matrix metalloproteinase 13 (MMP13, collagenase 3) during intestinal fibrosis in mice and in human tissue specimens.
We performed bulk RNA sequencing of paired intestinal biopsies taken from nonstenotic and stenotic areas of patients with CD (n=8). Corresponding tissue samples from healthy controls and CD patients with stenosis were used for immunofluorescence (IF) stainings. MMP13 gene expression was analyzed in cDNA of intestinal biopsies from healthy controls (n=51), patients with CD (n=137) and patients with ulcerative colitis (UC, n=57). In addition, gene regulation on RNA and protein level was studied in purified intestinal fibroblasts from mice upon IL36R stimulation. Finally, in vivo studies were performed with MMP13 deficient mice and wildtype controls in an experimental model of chronic intestinal inflammation and fibrosis. Ex vivo tissue analysis included stainings by Sirius Red and for intestinal cell populations and Collagen type VI by IF.
We observed that intestinal biopsies from stenotic areas as compared to nonstenotic regions of patients with CD showed increased levels of multiple proinflammatory cytokines including IL36G. Interestingly, MMP13 was detected within the 20 highest induced DEGs. IF analysis confirmed higher levels of MMP13 in stenotic tissue sections of CD patients as well as MMP13 expression by Pdpn+ and aSMA+ fibroblasts. Mechanistic experiments in vitro revealed that MMP13 expression was regulated by IL36R signaling, which was further confirmed by in vivo findings including studies using neutralizing anti-IL36R antibodies. Finally, MMP13 deficient mice as compared to wildtype controls developed less inflammation and fibrosis in an experimental model of chronic colitis characterized by reduced activation of myofibroblasts and Collagen type VI accumulation. These findings are consistent with a model suggesting a molecular axis involving IL36R activation and MMP13 expression during the pathogenesis of intestinal fibrosis.
Targeting IL36R-induced MMP13 expression could evolve as a promising strategy to interfere with the development of intestinal fibrosis.